1 / 46

Drug Manufacturing

Drug Manufacturing. BIT 230 Walsh Chapter 3. Drug Manufacturing. Most regulated of all manufacturing industries Highest safety and quality standards Parameters include: Design and layout of facility Raw materials Process itself Personnel Regulatory framework. Pharmacopeias.

Antony
Download Presentation

Drug Manufacturing

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. Drug Manufacturing BIT 230 Walsh Chapter 3

  2. Drug Manufacturing • Most regulated of all manufacturing industries • Highest safety and quality standards • Parameters include: • Design and layout of facility • Raw materials • Process itself • Personnel • Regulatory framework

  3. Pharmacopeias • Discussed before in other units and classes • Martindale- not a standards book • Gives information about drugs • Physiochemical properties • Pharmacokinetics • Uses and modes of administration • Side effects • Appropriate doses

  4. GMP guidelines • Different publications world wide, but generally have similar information • Go over everything from raw materials to the facility • US guidelines issues publications called “Points to Consider” for additional guidelines for newer biotech products (will go over these later in semester)

  5. Manufacturing facility • Most manufacturing facilities have requirements, but some specifics to biotech products, especially • Clean room • Water

  6. Clean Rooms • Clean room views • Environmentally controlled areas • Critical steps for bio/injectable drugs are produced in clean rooms • Contain high efficiency particulate air (HEPA) filters in the ceiling • Figure 3.1 page 98 of chapter

  7. Classification of Clean Roomsfor Pharma industry Class# microrganisms/m3 of air A <1 B 5 C 100 D 500 See table 3.5 page 100 of chapter

  8. Other considerations • Exposed surfaces – smooth, sealed, non-penetrable surface • Chemically-resistant floors and walls • Fixtures (lights, chairs, etc.) minimum and easily cleaned • Proper entry of materials and personnel into clean room to reduce risk of contamination in clean room

  9. Gowned person in Clean room

  10. Clean Room clothing • Covers most of operators body • Change in a separate room and enter clean room via an air lock • Clothing made from non-shredding material • Number of people in a clean room at once limited to only necessary personnel (helps with automated processes)

  11. CDS • Cleaning, decontamination and sanitization • C- removal or organic and inorganic material that may accumulate • D-inactivation and removal of undesired materials • S- destroying and removing viable microorganisms

  12. CDS cont’d • Done on surfaces that either are direct or indirect contact with the product • Examples of surfaces in both categories?

  13. CDS of process equipment • Of course trickier because comes in contact with the final product • Clean equipment, then rid equipment of cleaning solution • Last step involves exhaustive rinsing of equipment with pure water • WFI • Followed by autoclaving if possible • If possible use CIP (cleaning in place)

  14. Examples of CIP agents used to clean chromatography columns • 0.5-2.0 M NaCl • Non-ionic detergents • 0.1-1.0 M NaOH • Acetic Acid • Ethanol • EDTA • Protease

  15. Water • WFI- talked about this extensively before • 30,000 liters of WFI needed for 1kg of a recombinant protein • Use tap water just for non-critical tasks • Purified water – not as pure as WFI, but used for limited purposes (in cough medicines, etc.) • WFI used exclusively in downstream processing • Will not cover pages 105-112- water and documentation pages

  16. Sources of Biopharmaceuticals • Genetic engineering of recombinant expression systems • Your talks will be about types of systems and how they are used- mammalian cells, yeast, bacteria etc. • Most approved products so far produced in E. coli or mammalian cell lines

  17. E. coli • Cultured in large quantities • Inexpensive (relatively speaking) • Generation of quantities in a short time • Production facilities easy to construct anywhere in the world • Standard methods (fermentation) used

  18. Current products from E. Coli • tPA (Ekokinase) • Insulin • Interferon  • Interleukin-2 • Human growth hormone • Tumor necrosis factor

  19. Heterologous systems • Expression of recombinant proteins in cells where the proteins do not naturally occur • Insulin first in E. coli • Remember the drawbacks of expression in E. coli?

  20. Other problems with E. coli • Most proteins in E. coli expressed intracellularly • Therefore, recombinant proteins expressed in E. coli accumulate in the cytoplasm • Requires extra primary processing steps (e.g. cellular homogenization) and more purification (chromatography)

  21. Other problems with E. coli, cont’d • Inclusion bodies • Insoluble aggregates of partially folded product • Heterologous expressed proteins overload the normal protein-folding machinery • Advantage- inclusion bodies are very dense, so centrifugation can separate them from desired material

  22. Preventing inclusion bodies • Lower growth temperature (from 37C to 30C) • Use a fusion protein (thioredoxin) - native in E. coli – protein expressed at high levels and remains soluble

  23. Expression in animal cells • Major advantage- correct PT modifications • Naturally glycosylated proteins produced in: • CHO - Chinese hamster ovary • BHK - baby hamster kidney • HEK – human embryonic kidney

  24. Current products from animal cells • tPA • FSH • Interferon - • Erythropoietin • FSH • Factor VIIa

  25. Disadvantages of animal cells(compared to E. coli) • Complex nutritional requirements • Slower growth • More susceptible to damage • Increased costs • WILL NOT cover bottom of page 116 to page 124 (up to biopharmaceuticals)- you will cover these in your presentations

  26. Final Product Production • Focus on E. coli and mammalian systems • Process starts with a single aliquot of the Master Cell Bank • Ends when final products is in labeled containers ready to be shipped to the customer

  27. Production: Upstream and Downstream • Upstream: initial fermentation process; yields initial generation of product • Downstream: purification of initial product and generation of finished product, followed by sealing of final containers • biomanufacturing process overview

  28. Upstream processing • Remove aliquot from MCB • Inoculate sterile medium and grow (starter culture) • Starter culture used to inoculate larger scale production culture • Production culture inoculates bioreactor • Bioreactors few to several thousand liters • See figure 3.13 of chapter (page 129)

  29. Upstream cont’d • Pages 129-133 go over specific details for microbial fermentation • Pages 133-134 go over specific details for animal cell culture • Properties of animal cells • Anchorage dependent • Grow as a monolayer • Contact inhibited • Finite lifespan • Longer doubling times • Complex media requirements

  30. Downstream processing • Diagram page 135 of chapter 3 • Detailed steps considered confidential • Clean room conditions for downstream

  31. Downstream cont’d • Steps involved (intracellular products – E. coli.) – mammalian products secreted in media, so easier to isolate) • Centrifugation or filtration • Homogenization • Removal of cellular debris • Concentration of crude material (by precipitation or ultra filtration) • High resolution chromatography (HPLC) • Formulation into the final product

  32. Downstream cont’d • Final product formulation • Chromatography yields 98-99% pure product • Add excipients (non active ingredients), which may stabilize the final product • Filtration of final product, to generate sterile product • Freeze drying (lyophilization) if product if to be sold as a powder (dictated by product stability)

  33. Separation methods • Page 142,tables 3.18 and 3.19 • Familiar with: • Ion-exchange • Gel-filtration • Affinity chromatography • Protein A chromatography • Immunoaffinity chromatography

  34. Factors that influence biological activity • Denature or modify proteins • Results in loss of/reduced protein activity • Need to minimize loss in downstream work • Problems can be chemical (e.g., oxidizing, detergents); physical (e.g., pH, temperature); or biological (e.g., proteolytic degradation) • Table 3.20 page 143

  35. Proteolytic degradation • Hydrolysis of one or more peptide bonds • Results in loss of biological activity • Trace quantities of proteolytic enzymes or chemical influences • Several classes of proteases: • Serine • Cysteine • Aspartic • Metalloproteases (also in other ppt)

  36. Protease inhibitors • PMSF – serine and cysteine proteases • Benzamidine – serine proteases • Pepstatin A – aspartic proteases • EDTA – metalloproteases • a.a residue known to be present at active site of protein, so disruption of it causes loss of activity

  37. Others (mentioned before) • Deamidation – hydrolysis of side chain of asparagine and glutamine • Happens at high temp and extreme pH • Oxidation and disulphide exchange • Oxidation by air (met and cys in particular) • Alterations of glycosylation patterns in glycoproteins (more than one sugar) • Affect activity or immunological properties

  38. Excipients • Substances added to final product to stabilize it • Serum albumin • Withstands low pH or elevated temps • Keeps final product from sticking to walls of container • Stabilize native conformation of protein

  39. Excipients cont’d • Amino acids • Glycine – stabilizes interferon, factor VIII, stabilizes against heat • Alcohols (and other polyols) • Stabilize proteins in solution • Surfactants • Reduces surface tension; proteins don’t aggregate, so don’t denature

  40. Final product fill • See figure 3.27 page 153 • Bulk product gets QC testing • Passage through 0.22 m filter for final sterility • Aceptically filled into final product containers • Uses automated liquid handling systems

  41. Final product fill cont’d • Freeze drying (lyophilization) • Yields a powdered product • Reduces chemical and biological degradation of final product • Longer shelf life than products in solution • Storage for parenteral products (those administered intravenously or injected)

  42. Freeze drying cont’d • Need to add cryoprotectors • Glucose or sucrose • Serum albumin • Amino acids • Polyols • Freeze drying can be done in many steps

  43. Labeling and Packing • After sealed in final container, product quarantined • Samples are QC’d • Check potency, sterility and final volume • Detection and quantitation of excipients • Highly automated procedures • Labeling function critical- biggest error where many products are made

  44. Label • Name and strength of product • Specific batch number • Date of manufacture and expiry date • Required storage conditions • Name of manufacturer • Excipients included • Correct mode of usage

  45. Other final product items • Biopharmaceutical products undergo more testing than traditional pharma products • Products made in recombinant systems have more potential to be contaminated than synthetic chemical drugs • Larger, more complex molecules

More Related